20/20 Biolabs, Inc.(AIDX)— Stock Profile, AI Score & Financials

Technology · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

20/20 Biolabs, Inc. (AIDX) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores AIDX at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,520 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), 20/20 Biolabs, Inc. reports quarterly revenue of $730.6K, net income of $-1.5M. Top institutional holders of AIDX by reported 13-F value include Cresset Asset Management, HRT FINANCIAL, VANGUARD FIDUCIARY, based on the most recent SEC filings. AIDX trades on the Nasdaq exchange and files with the SEC under CIK 1139685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 20/20 Biolabs, Inc. directly from SEC EDGAR.